GlobalData on MSN3d
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
BioSpace1d
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
GEN3d
Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
The American Journal of Managed Care3d
FDA Approves Acoramidis for ATTR-CM
With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...
BioSpace5d
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
On Friday, the FDA approved BridgeBio Pharma, Inc.’s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) ...
Alnylam Pharmaceuticals: Strategic Positioning and Growth Opportunities Reinforce Buy Rating Amidst Competitive ATTR-CM Market
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...
STAT12h
BridgeBio wins FDA approval for heart disease drug
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the condition in over five years and ...
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...
BridgeBio announces FDA approved Attruby for ATTR-CM patients
Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...
TCTMD8d
Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression
By targeting the TTR gene directly in the liver, the therapy “has opened up the door” to permanent treatment, says Sarah ...